|
|
| | Benzamide, N-[(5-chloro-2-propoxyphenyl)methyl]-4-fluoro-N-[2-[4-[(2-propyn-1-ylamino)sulfonyl]phenyl]ethyl]- Basic information |
| | Benzamide, N-[(5-chloro-2-propoxyphenyl)methyl]-4-fluoro-N-[2-[4-[(2-propyn-1-ylamino)sulfonyl]phenyl]ethyl]- Chemical Properties |
| Boiling point | 697.6±65.0 °C(predicted) | | density | 1.283±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 9.30±0.50(predicted) |
| | Benzamide, N-[(5-chloro-2-propoxyphenyl)methyl]-4-fluoro-N-[2-[4-[(2-propyn-1-ylamino)sulfonyl]phenyl]ethyl]- Usage And Synthesis |
| Uses | MS-II-124 is an effective and selective NLRP3 inhibitor (IC50=0.12 μM) with anti-inflammatory and immunomodulatory activities, which can be used in the research of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS)[1]. | | in vivo | MS-II-124 (10 mg/kg; i.p.; single dose) reduces lung inflammation and immune cell infiltration in the LPS (HY-D1056) ( i.n. instillation, 40 μg in 40 μL PBS) -induced ALI/ARDS wild-type mouse model, exhibiting anti-inflammatory and immunomodulatory activities[1]. | Animal Model: | ALI/ARDS WT C57BL/6 mice model[1]. | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.), Single dose. 1 h before i.n. instillation of LPS (40 μg in 40 μL PBS). | | Result: | Significantly inhibited lipopolysaccharide (LPS)-induced IL-1β production in pulmonary bronchoalveolar lavage fluid (BALF), whereas NLRP3 deletion did not significantly inhibit its production. |
| | References | [1] Xu Y, et al. Characterization of a small molecule inhibitor of the NLRP3 inflammasome and its potential use for acute lung injury[J]. Bioorganic Chemistry, 2024: 107562. DOI:10.1016/j.bioorg.2024.107562 |
| | Benzamide, N-[(5-chloro-2-propoxyphenyl)methyl]-4-fluoro-N-[2-[4-[(2-propyn-1-ylamino)sulfonyl]phenyl]ethyl]- Preparation Products And Raw materials |
|